Oral GLP-1s: one molecule has a pill, and the other one does not
Swallowing the drug instead of injecting it is the single most popular request in this market, and the market has answered it twice: once with an approved tablet, and once with a compounded product built to look like one. Semaglutide is the molecule with the tablet. Tirzepatide has no oral form approved anywhere, no randomized trial of one indexed in PubMed, and a price on a great many telehealth menus anyway.
What this comes down to
- The FDA-approved oral GLP-1 is semaglutide, sold as WEGOVY tablets and as RYBELSUS. Both come with a dosing ritual: an empty stomach, at most four ounces of water, and a 30-minute wait before food, drink or any other oral medication.
- The openFDA label API returns only injections for tirzepatide — MOUNJARO, ZEPBOUND and their pens. There is no approved oral tirzepatide to be a version of.
- Fifteen of the 257 sellers we have read price an oral, sublingual or dissolving tirzepatide, from $159 a month — for a route of administration no approved product uses.
- PubMed returns zero randomized trials of oral or sublingual tirzepatide. The identical filter returns 51 for oral semaglutide, so the filter finds trials in this field when there are any.
The approved pill, and the ritual it comes with
Semaglutide is a peptide, and peptides are destroyed by the gut. The approved tablet gets around that with an absorption enhancer and a set of instructions that are part of the product rather than advice around it. The label tells the patient to take it on an empty stomach in the morning with water, up to four ounces, to swallow it whole without splitting, crushing, chewing or dissolving it, and to wait at least 30 minutes before eating, drinking anything else, or taking any other oral medication[1]. Those are not comfort tips. They are the conditions under which the drug was measured.
The instruction on the approved tablet is to swallow it whole and specifically not to dissolve it. A sublingual troche, a rapid-dissolve tablet or a lozenge is doing the opposite thing on purpose, which means whatever was measured for the approved tablet was measured on a different product than the one in the pouch.
There are two approved oral semaglutide products and they are indicated for different things. RYBELSUS is indicated for glycemic control in adults with type 2 diabetes and for cardiovascular risk reduction in that population[2]. The WEGOVY tablet is indicated for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain the reduction long term[1]. A weight-loss prescription written against the diabetes product is an off-label prescription, which is legal and is also not the same thing as an approved use — the brand-versus-compounded rules set out why that distinction keeps mattering.
There is no oral tirzepatide, and there never has been
Asked for every brand name whose generic ingredient is tirzepatide, the openFDA label API returns six spellings, and every one of them is an injection: MOUNJARO, Mounjaro, Mounjaro KwikPen, ZEPBOUND, Zepbound and Zepbound KwikPen[3]. Asked the same question about semaglutide it returns OZEMPIC, Ozempic, RYBELSUS and WEGOVY, two of which are tablets. A fabricated ingredient name returned an HTTP 404 in the same session, so an empty answer there means an empty answer rather than a broken query.
PubMed, via the E-utilities API
("oral tirzepatide"[tiab] OR (tirzepatide[tiab] AND sublingual[tiab])) AND "randomized controlled trial"[pt] AND "humans"[mh]Returned 0. Positive control — oral semaglutide, identical filter — returned 51 through the identical filter in the same session.
The control is deliberately the same question asked of the other molecule, because what is being tested is whether the filter can find oral-GLP-1 trials at all. It can — 51 of them. Dropping the trial filter entirely, tirzepatide with an oral, sublingual or orally disintegrating term returns 2 records in total, against 129 for orforglipron, a small-molecule oral agonist that has actually been through phase 3.
That is worth stating plainly, because the marketing does not. A compounded tirzepatide troche is not a cheaper version of an approved pill. It is a dosage form that has never been through a trial[4], of a molecule whose approved products are all injections, and the argument for it is the manufacturing argument rather than the evidence one. The drug being built to actually be a tablet is a different molecule entirely — a small one, which is why it survives the gut — and it is still in the pipeline. What third-party testing proves is the article about that argument.
What the roster prices, and how the two kinds sit side by side
Across the 257 sellers on our price roster, 34 publish 61 priced lines for something you swallow or dissolve, from $99 to $448.79 a month. Twelve of those lines are the approved brand tablet, sold by six sellers including NowPatient, NovoCare Pharmacy, ZipHealth and three more. The rest are compounded, and the difference between the two is not visible in the price. Our price method explains how each figure is read, and the calculator is where a medication price and a membership fee stop being the same number.
| Seller | What it is called | A month |
|---|---|---|
| Strut Health | semaglutide lozenges, bottom of the published range | $99 |
| NowPatient | wegovy tablets, per order | $99 |
| NEUVÉ Health | semaglutide sublingual microdose, monthly program fee | $138 |
| Vigormeds | compounded semaglutide sublingual, published floor | $139 |
| YOURx Health | compounded semaglutide rapid-dissolve tablet, monthly | $139 |
| NovoCare Pharmacy | Wegovy tablets 1.5 mg | $149 |
| NovoCare Pharmacy | Ozempic tablets 1.5 mg | $149 |
| ZipHealth | Wegovy Pill 1.5 mg and 4 mg | $149 |
| Knownwell | Wegovy Pill, 1.5 mg | $149 |
| SkinnyRx | compounded semaglutide tablets, first month | $149 |
| Vigormeds | compounded tirzepatide sublingual, published floor | $159 |
| Nolu | oral semaglutide, twelve-month plan | $159 |
| YOURx Health | compounded tirzepatide rapid-dissolve tablet, monthly | $159 |
| MyDrHank | oral semaglutide, from price | $171 |
Oral, sublingual and dissolving GLP-1 lines on our roster, cheapest first
- Ask whether the product is the approved tablet or a compounded one. The answer changes what evidence exists for the thing in your hand, and it is rarely on the product page.
- Ask which pharmacy compounds it, and whether that pharmacy is a state-licensed 503A or an FDA-registered outsourcing facility. Only the second is subject to current good manufacturing practice requirements[5]; how to check either one is a short and mostly public exercise.
- Ask what dose you are getting in milligrams, not in tablets. Milligrams, milliliters and units is where that arithmetic goes wrong most often.
- Ask what month two costs. An introductory oral price and a maintenance oral price are frequently different numbers on the same page.
Questions people actually ask
Is there an FDA-approved GLP-1 pill?
Yes, for semaglutide. WEGOVY tablets and RYBELSUS are both approved oral semaglutide products, with different indications. They are taken on an empty stomach with a small amount of water and followed by a 30-minute wait before anything else.
Is there an oral tirzepatide?
Not an approved one. Asked for every brand whose active ingredient is tirzepatide, the openFDA label API returns six names and all six are injections. PubMed indexes no randomized trial of an oral or sublingual tirzepatide, while the identical filter returns 51 trials for oral semaglutide.
Are sublingual and rapid-dissolve versions the same as the approved tablet?
No. The approved tablet's own instructions say to swallow it whole and not to split, crush, chew or dissolve it. A troche or a rapid-dissolve tablet is designed to do the opposite, so the approved product's measurements were taken on a different thing.
Why would a pill cost less than an injection?
Often it is not the dosage form that is cheaper but the dose, the term you commit to, or the fact that the product is compounded rather than branded. Comparing an oral line with an injectable line on headline price alone usually compares two different commitments.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.WEGOVY (semaglutide) injection and tablets — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated June 2026The label served from DailyMed on 2026-09-12 carries an SPL effective time of 20260618 and covers both WEGOVY injection and WEGOVY tablets. Its dosing section directs the patient to take the tablet on an empty stomach in the morning with water up to four ounces, to swallow it whole without splitting, crushing, chewing or dissolving it, and to wait at least 30 minutes before food, other beverages or other oral medications. Its indications for WEGOVY tablets are cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, and reduction and long-term maintenance of excess body weight.
- 2.RYBELSUS (semaglutide) tablets — FDA prescribing information. U.S. Food and Drug Administration, Structured Product Labeling, 2026. Source · Document dated January 2026The RYBELSUS Structured Product Labeling record returned by the openFDA label API carries an effective time of 20260130 and states that the product is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events.
- 3.Structured Product Labeling, queried through the openFDA label API. U.S. Food and Drug Administration, 2026. SourceCounting brand names by active ingredient on 2026-09-12 returned six spellings for tirzepatide — MOUNJARO, Mounjaro, Mounjaro KwikPen, ZEPBOUND, Zepbound and Zepbound KwikPen — every one an injection, and four for semaglutide: OZEMPIC, Ozempic, RYBELSUS and WEGOVY. A fabricated generic name returned HTTP 404 and a fabricated brand name returned NOT_FOUND in the same session.
- 4.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-12, oral or sublingual tirzepatide through the randomized-trial and human-indexing filter returned 0, while oral or sublingual semaglutide through the identical filter returned 51 and semaglutide alone returned 316. Without the trial filter, tirzepatide with an oral, sublingual or orally disintegrating term returned 2 records and orforglipron returned 129.
- 5.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements; drugs compounded by a licensed pharmacist in a state-licensed pharmacy under section 503A are not. The page's own line reads Content current as of: 09/16/2025.
Key figures